Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• With the exception of type 2 diabetes mellitus (T2DM), is in generally good health

• Has a history of T2DM for ≥1 year at the time of screening based on self-reporting

• Has a baseline HbA1C level of ≤10% at the time of screening

• Has a stable weight (based on self-reporting) defined as ≤5 kg gain or loss of bodyweight for at least 3 months before Visit 1/Screening

• T2DM treated with lifestyle modification alone or with stable doses (no significantchange for ≥3 months from Visit 1/Screening, based on self-reporting) of ≤ 3 oralanti-diabetic medications and anticipated not to require dose adjustments during thestudy duration

• Body mass index (BMI) between 25 and 40 kg/m2, inclusive

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Has known systemic hypersensitivity to the MK-2828 drug substance or othernucleotide-binding, leucine-rich, protein 3 inhibitor (NLRP3i) based therapy, itsinactive ingredients, or the placebo

• Has a history of congestive heart failure (New York Heart Association [NYHA] Class 3or 4)

• Has a history of myocardial infarction, uncontrolled arrhythmias, cardiacrevascularization, unstable peripheral arterial disease and/or stroke within 6months of screening

• History of significant multiple and/or severe allergies (e.g., food, drug, latexallergy), or has had an anaphylactic reaction or significant intolerability (i.e.,systemic allergic reaction) to prescription or nonprescription drugs or food

• Has type 1 diabetes mellitus or secondary types of diabetes

• Has experienced complications of diabetes such as ketoacidosis, unstable diabeticretinopathy, or maculopathy

• Has previous or planned (during the trial period) obesity treatment with surgery ora weight loss device